Immune & Thymic
VIP
Also published as Vasoactive intestinal peptide, Aviptadil
A 28 amino acid neuropeptide of the secretin glucagon family, widely distributed in the nervous system and gut. It is a potent vasodilator, a bronchodilator and an anti-inflammatory signal, and it sets the circadian rhythm in the suprachiasmatic nucleus.
Where it came from
Isolated from porcine intestine by Sami Said and Viktor Mutt in 1970.
What the literature examines
- VPAC1 and VPAC2 receptor signalling
- Pulmonary arterial hypertension and bronchodilation, in human trials of inhaled aviptadil
- Circadian pacemaking in the suprachiasmatic nucleus
- Anti-inflammatory signalling in autoimmune models
- Acute respiratory failure, in COVID-19 era trials of intravenous aviptadil
State of the evidence
Aviptadil, the synthetic form, has been through registered human trials. The COVID-19 trial results were contested and the FDA declined emergency authorisation.
What a buyer should know
Circulating half life is on the order of a minute or two, which is the central practical fact about VIP and the reason clinical work uses inhaled or infused routes. Systemic vasodilation is the dose limiting effect, not an incidental one.
Handling and stability
Notably unstable, both to enzymatic degradation and to surface adsorption. Among the more demanding peptides in this catalogue to handle well.
Read it yourself
We do not publish a curated citation list, because a hand picked list of papers is a sales tool. These links run a live query against the public databases, so you see everything, including the results that do not suit us.
Supplied for laboratory research use only. Nothing on this page is a dose, a protocol or a claim of effect in humans, and nothing here is medical advice. Read our research use policy.